osteoarthritis
OSTEOARTHRITIS

Osteoarthritis is a chronic progressive disease where there is degeneration & loss of articular cartilage that occurs together with new bone formation at the joint surfaces and margins, that causes pain and deformity.

The patient experiences pain, stiffness, decreased movement, inflammation and crepitus.

The pain is usually aggravated by pain and relieved by rest.

Differential Diagnosis

  • Rheumatoid arthritis (RA)
    • Distinguishing features:
      • Morning stiffness
      • Positive rheumatoid factor
      • Positive anti-CCP antibody
      • Increased ESR & C-reactive protein
  • Septic arthritis
    • Positive synovial fluid culture
  • Seronegative arthritis
    • Inflammatory arthropathies which affects >1 joint
      • Ankylosing spondylitis
      • Reactive arthritis
        • Recent history of an infection, usually of the urinary tract, precedes joint pain
    • Psoriatic arthritis
      • Presence of psoriasis
  • Crystal arthropathies
    • Gout
      • Increased serum uric acid levels
      • Presence of tophi
    • Pseudogout
      • Pattern by which joints are affected; the knees are initially affected, followed by the metacarpophalangeal joints, hips, shoulders & elbows
  • Ligament injury
    • Sudden onset of pain after strenuous activity
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.